A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Modulation

Executive Summary: A 83-01 is a small-molecule inhibitor targeting ALK-5, ALK-4, and ALK-7 receptors, with an IC₅₀ of ~12 nM for TGF-β-mediated signaling inhibition in vitro (APExBIO). It suppresses Smad-dependent transcription with high selectivity, showing minimal effects on BMP signaling at ≤1 μM (Anvar et al., 2024). This compound is widely used in differentiation protocols for human stem cells and in studies dissecting EMT and cellular growth inhibition. Its physicochemical properties support robust solubility in DMSO and ethanol, but not water. A 83-01 is recommended for storage at -20°C and finds extensive application in organoid, fibrosis, and cancer biology research (APExBIO).

Biological Rationale

The transforming growth factor-beta (TGF-β) signaling pathway regulates cell differentiation, proliferation, and extracellular matrix production. Dysregulation is implicated in cancer, fibrosis, and abnormal tissue remodeling (Anvar et al., 2024). ALK-5, ALK-4, and ALK-7 are type I activin/nodal receptors mediating TGF-β signals via Smad-dependent transcription. Inhibition of these kinases blocks downstream effects, including epithelial-mesenchymal transition (EMT) and fibrotic responses. Selective inhibition enables dissection of TGF-β's roles in developmental and disease models. A 83-01, offered by APExBIO, is designed for high affinity and selectivity against ALK-5, with limited off-target activity against BMP receptors.

Mechanism of Action of A 83-01

A 83-01 is a selective ATP-competitive inhibitor of the ALK-5 (TGF-βRI), ALK-4, and ALK-7 serine/threonine kinase domains. By binding to the kinase active site, it prevents phosphorylation of receptor-regulated Smads (R-Smads), primarily Smad2/3 for ALK-5. This results in suppression of Smad-dependent gene transcription. In luciferase reporter assays, A 83-01 inhibits ALK-5-mediated transcription with an IC₅₀ of ~12 nM. At 1 μM, it achieves 68% inhibition in Mv1Lu cell-based readouts. Importantly, at concentrations up to 1 μM, A 83-01 does not significantly inhibit BMP4-induced transcription in C2C12 cells, but higher concentrations (>3 μM) can modestly reduce BMP activity (Anvar et al., 2024).

Evidence & Benchmarks

• A 83-01 inhibits TGF-β/ALK-5-mediated Smad transcription in vitro with an IC₅₀ of ~12 nM (Mv1Lu cells) (APExBIO).
• 68% inhibition of ALK-5-induced luciferase reporter activity is achieved at 1 μM in cellular assays (APExBIO).
• At 1 μM, A 83-01 does not significantly affect BMP4-induced transcription in C2C12 cells; slight suppression is seen only above 3 μM (Anvar et al., 2024).
• In human ESC differentiation, dual inhibition of activin/nodal (A 83-01) and FGF2 pathways enhances trophoblast lineage specification, as measured by HLA-G, KRT7, and hCG markers (Anvar et al., 2024).
• The compound is soluble at >21.1 mg/mL in DMSO and >9.82 mg/mL in ethanol; insoluble in water (APExBIO).

This article extends 'Strategic Modulation of TGF-β Signaling with A 83-01' by providing granular, quantitative benchmarks and updated differentiation data in human stem cell models.

It also clarifies the application scope compared to 'A 83-01 in Organoid Modeling', emphasizing dual inhibition strategies and selectivity boundaries.

Applications, Limits & Misconceptions

A 83-01 is widely used in:

• Epithelial-mesenchymal transition (EMT) research and cellular growth inhibition studies.
• Differentiation of human embryonic stem cells (hESCs) to trophoblast-like cells using dual inhibition protocols (Anvar et al., 2024).
• Organoid modeling for disease and developmental biology (A 83-01: Precision ALK-5 Inhibition for Organoid Modeling), offering expanded practical integration guidance over this prior review.
• Cancer biology and fibrosis research, where TGF-β signaling is dysregulated.

Common Pitfalls or Misconceptions

• A 83-01 is not a broad-spectrum TGF-β superfamily inhibitor; it is selective for ALK-5/4/7 and does not significantly inhibit BMP signaling at standard concentrations (Anvar et al., 2024).
• It is ineffective in water-based buffers due to insolubility; DMSO or ethanol must be used for stock solutions (APExBIO).
• Long-term storage at temperatures above -20°C or repeated freeze-thaw cycles can reduce compound activity.
• Concentrations above 3 μM may impact BMP signaling, confounding interpretation in mixed pathway studies.
• It does not block non-Smad TGF-β signaling branches, such as TAK1 or MAPK pathways.

Workflow Integration & Parameters

A 83-01 (CAS 909910-43-6) is supplied as a solid by APExBIO (A 83-01), with recommended storage at -20°C. For experimental use, prepare stock solutions in DMSO (>21.1 mg/mL) or ethanol (>9.82 mg/mL with warming/ultrasonication). Avoid aqueous solutions to prevent precipitation. In hESC differentiation, typical concentrations range from 0.5–2 μM, with 1 μM commonly used for dual inhibition with FGF2 pathway blockers. For ALK-5/4/7 inhibition in EMT or cancer models, concentration optimization is advised (0.01–3 μM). Minimize light and repeated freeze-thaw exposure. For extended applications and troubleshooting, consult the A3133 kit documentation and refer to established protocols (Anvar et al., 2024).

Conclusion & Outlook

A 83-01 is a validated, selective inhibitor of ALK-5, ALK-4, and ALK-7, enabling precise modulation of TGF-β/activin/nodal signaling in stem cell, EMT, organoid, and cancer biology research. Its potency, selectivity, and solubility profile make it a preferred reagent for translational studies requiring suppression of Smad-dependent transcription. Researchers are advised to monitor concentration, solubility, and pathway selectivity for best results. Future work will further clarify its role in advanced human disease modeling and combinatorial differentiation strategies. For more information or to purchase, see the A 83-01 product page.